Finance News – Novo Nordisk
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly
Concerns about pricing pressure and trade policies have led to a substantial decline in market value for companies specializing in obesity treatments, impacting investor confidence...
Read Full Article →Novo Nordisk Stock Drops Further on Bank of America Downgrade
Shares of Novo Nordisk experienced a decline following an evaluation by Bank of America, reflecting investor concerns and potentially impacting the company’s market valuation and s...
Read Full Article →How Novo Nordisk lost its lead in the weight loss race
Novo Nordisk faced challenges meeting surging demand and navigating a market heavily influenced by celebrity endorsements, which impacted its financial performance and competitive...
Read Full Article →Novo Nordisk cuts sales forecasts for its once-blockbuster weight loss drugs
Novo Nordisk's lowered projections reflect ongoing challenges from increased competition and weaker global demand, which together are impacting the revenue potential of its weight...
Read Full Article →Trump’s 15% tariff on medicines will harm patients, say EU drugmakers
The introduction of a 15% import duty on European medicines is expected to increase costs, disrupt supply chains, and negatively impact pharmaceutical companies' market valuations...
Read Full Article →Wegovy maker Novo Nordisk’s shares plunge as it cuts sales forecast
Novo Nordisk’s decision to lower its annual revenue and profit expectations has led to a significant drop in its stock value, reflecting investor concerns about the company’s compe...
Read Full Article →Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
Novo Nordisk's recent reduction in projected earnings coupled with leadership changes has led to a notable decline in its stock value among investors.
Read Full Article →Novo Nordisk shares plunge 26% after naming new CEO, cutting full-year guidance
The company's announcement of a leadership change alongside reduced projections for annual revenue and earnings contributed to a notable decline in its stock value.
Read Full Article →Novo Nordisk shares plunge 23% on profit warning amid US weight-loss drug competition
The company experienced a significant decline in market value following a reduced profit forecast, reflecting increased challenges in the competitive landscape of weight-loss medic...
Read Full Article →Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
Novo Nordisk lowered its forecast due to increasing challenges from various competitors, leading to a decline in its stock value and signaling potential impacts on the company's fu...
Read Full Article →Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
The termination of the collaboration by Novo Nordisk has led to a significant decline in Hims & Hers' market value, reflecting investor concerns over the allegations and potential...
Read Full Article →Hims & Hers Stock Plunges 33% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
The termination of the collaboration with Novo Nordisk has led to a significant decline in Hims & Hers’ market value, reflecting investor concerns about the company’s operational c...
Read Full Article →Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
The termination of the collaboration between Hims & Hers and Novo Nordisk triggered a substantial decline in Hims & Hers’ share value, reflecting investor concerns about the compan...
Read Full Article →Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Shares of Novo Nordisk declined following underwhelming results from their recent obesity treatment study, raising concerns among investors about the drug’s potential market impact...
Read Full Article →A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
Novo Nordisk is expected to face substantial financial losses as Canada prepares to introduce generic alternatives of its weight loss medication due to the company’s failure to mai...
Read Full Article →After ousting CEO, Novo Nordisk reclaims crown as largest European company
Following the unexpected leadership change, the pharmaceutical company regained its position as the top European firm based on market value, highlighting its strong financial stand...
Read Full Article →Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk’s medications associated with uncommon but severe eye issues may impact the company’s valuation, as emerging health technology firms continue to gain significant inves...
Read Full Article →Novo Nordisk Stock Climbs on Report of Activist Investor Parvus Building Stake
Shares of Novo Nordisk rose following news that activist investor Parvus has been gradually acquiring a notable portion of the company’s equity, potentially influencing future stra...
Read Full Article →Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
An investment firm has increased its holdings in the Danish pharmaceutical company known for its diabetes treatment, signaling confidence amid leadership changes and recent decline...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s Evernorth division reached an agreement that aims to reduce out-of-pocket expenses for employers and employees on certain weight management medications from Eli Lilly and N...
Read Full Article →Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →Ozempic-maker Novo Nordisk ousts CEO after shares plummet
Novo Nordisk's decision to replace its CEO follows a significant decline in the company’s stock value, underscoring the financial impact of recent market challenges on the pharmace...
Read Full Article →Novo Nordisk CEO steps down amid growing competition for weight loss drugs
The departure of the longstanding CEO coincides with increased market challenges in the weight management sector, potentially impacting the company's strategic direction and future...
Read Full Article →Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The departure of the CEO at the Danish pharmaceutical company is expected to impact investor confidence as the firm navigates increased market rivalry and aims to sustain its finan...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Here’s how much extra weight is lost with Zepbound over Wegovy
A recent comparison of two popular weight-loss medications highlighted a measurable difference in effectiveness, potentially influencing market share and revenue for the companies...
Read Full Article →